BioXcel Therapeutics ROCE 2024

Mit csinál BioXcel Therapeutics?

BioXcel Therapeutics Inc. is a biotechnology company based in New Haven, CT, USA, focused on the development of novel therapeutics for severe neurological and psychiatric diseases as well as cancer. The company was founded in 2017 and is listed on the NASDAQ stock exchange. The founding of BioXcel Therapeutics Inc. was based on the concept that the combination of state-of-the-art data analytics technologies such as artificial intelligence (AI) and big data analysis with traditional biomedical approaches can open new opportunities in the field of drug discovery and development. The company utilizes its extensive database of clinical, genetic, molecular, and other data to identify targets and molecules that show promise for treating severe diseases. The business model of BioXcel Therapeutics Inc. includes both internal development and a licensing and partnership strategy. The company is working on various projects currently in different stages of clinical development. The key therapeutics currently in the company's pipeline include BXCL501, BXCL701, and BXCL702. BXCL501 is a novel treatment approach for acute anxiety and agitation in patients with schizophrenia, bipolar disorders, and Alzheimer's disease. The drug is based on a combination of DEX, an alpha-2 agonist, and melatonin. The company is currently planning a Phase III trial for BXCL501. BXCL701 is an oral immunoncology drug based on the inhibition of interleukin-12 and -23 and has the potential to treat various types of cancer. The drug is still in the clinical development phase. BXCL702 is a novel approach to treating pain in patients with peripheral neuropathic pain. The drug is currently in the preclinical development phase. BioXcel Therapeutics also operates a licensing and partnership strategy for drug development and commercialization. In November 2019, the company entered into an exclusive global licensing agreement with Nocion Therapeutics, a company specializing in the development of drugs for localized pain. Under this agreement, BioXcel Therapeutics will pursue the development and commercialization of Nocion's technology platform for the delivery of anesthetic drugs to patients with peripheral neuropathy. The company has also partnered with the Zambon Group, a leading European company in pharmaceutical and biotechnology research and development, and has entered into a research collaboration with Eisai Co. Ltd. BioXcel Therapeutics is an innovative company that combines the benefits of state-of-the-art data analytics technologies with traditional biomedical approaches to develop therapeutics for severe neurological and psychiatric diseases as well as cancer. The company has a well-stocked pipeline of promising drugs in various stages of clinical development and an effective licensing and partnership strategy that allows for further growth. BioXcel Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.